Vaccinex to delist Common Stock from Nasdaq due to decision; stock suspended since Dec 18, 2024.
On March 7, 2025, Vaccinex, Inc. (OTC: VCNX), a clinical-stage biotechnology company, revealed its plan to delist its common stock from Nasdaq after suspending trading since December 18, 2024. The Company's innovative approach targets neurodegenerative diseases by inhibiting SEMA4D to block astrogliosis and neuroinflammation. Vaccinex notified Nasdaq of its decision to cease trading the Common Stock, valued at $0.0001 per share.